Both in Pharmaceuticals
Apimeds Pharmaceuticals US vs Skye Bioscience
Over the past year APUS returned −81.9% and SKYE returned −84.8%; their daily moves had a correlation of 0.03.
APUS −81.9% SKYE −84.8%Growth of $1, one year, split-adjusted
| Metric | APUS | SKYE |
|---|---|---|
| Price | $3.29 | $1.62 |
| Market cap | $5.0M | $7.2M |
| Today | −6.00% | +5.88% |
| 1 month | +97.0% | −9.0% |
| 6 months | — | −75.5% |
| Year to date | −79.9% | −73.0% |
| 1 year | — | −85.3% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | -$8.6M | $9.9M |
| Dividend yield | — | — |
| Volatility (60d) | 279.1% | 616.8% |
| Short % of float | 1.0% | 0.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).